A spikevax vial in Viersen, Germany, on Dec. 9, 2021. (Ralf Liebhold/Shutterstock) In a blow to Moderna’s COVID-19 vaccine patent war against Arbutus Biopharma, a federal judge on Wednesday adopted the latter’s interpretation of key technical terms in the disputed patents.
Arbutus sued Moderna in February 2022, seeking damages tied to patents Moderna allegedly infringed with the production and sale of its Spikevax vaccine. Spikevax is a messenger RNA, or mRNA vaccine, meaning that it carries mRNA molecules that can instruct the body’s cells to produce a protein from the COVID-19 virus to trigger an immune response.
Those patents pertain to the technology of making lipid nano-particle (LNP), which relies on fat-like molecules, called lipids, to encapsulate and protect nucleic acids like mRNA from degradation in the human body. These various lipids exist in specified ratios, expressed in terms of the “mol percentage,” or the percentage of each type of lipid […]
Read the Whole Article From the Source: www.theepochtimes.com
